Langzeitverlauf bei 60 Patienten mit alveolarer Echinokokkose unter Dauertherapie mit Mebendazol (1976-85). [The long-term course of 60 patients with alveolar echinococcosis in continuous therapy with mebendazole (1976-85)]

Détails

ID Serval
serval:BIB_E006CFACE198
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Langzeitverlauf bei 60 Patienten mit alveolarer Echinokokkose unter Dauertherapie mit Mebendazol (1976-85). [The long-term course of 60 patients with alveolar echinococcosis in continuous therapy with mebendazole (1976-85)]
Périodique
Klinische Wochenschrift
Auteur(s)
Ammann  R., Tschudi  K., von Ziegler  M., Meister  F., Cotting  J., Eckert  J., Witassek  F., Freiburghaus  A.
ISSN
0023-2173 (Print)
Statut éditorial
Publié
Date de publication
11/1988
Volume
66
Numéro
21
Pages
1060-73
Notes
English Abstract
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Nov 1
Résumé
Since 1976 60 patients with inoperable alveolar echinococcosis caused by Echinococcus multilocularis were treated with high doses of mebendazole and examined at regular intervals prospectively according to our protocol regarding clinical course, liver function, morphology, immunologically and plasma mebendazole levels. The average duration of disease was 8(1-19) years, the average duration of chemotherapy was 4.25 (0.75-9) years. The long term results showed a correlation of the clinical course with the mean plasma mebendazole levels and the duration of chemotherapy, respectively. Death (n = 5) or transient progression of the disease process (n = 14) was observed primarily in patients with low plasma mebendazole levels in the early course and within the first two years of chemotherapy. Only 9 patients showed a decrease of the parasite mass. Immundiagnosis (total serum IgE and serum antibodies against Echinococcus antigen) gave some information with regard to therapy results, but only in the long-term course. The cumulative survival of the patients under study was 96% at 5 years and 84% at 10 years, respectively which is markedly higher compared to historical control series with a letality of greater than 90% within 10 years.
Mots-clé
Adult Aged Animals Echinococcosis, Hepatic/*drug therapy/immunology Echinococcosis, Pulmonary/*drug therapy/immunology Echinococcus/immunology Female Follow-Up Studies Humans Immunoglobulin E/analysis Liver Function Tests Long-Term Care Male Mebendazole/*administration & dosage Middle Aged
Pubmed
Web of science
Création de la notice
24/01/2008 17:41
Dernière modification de la notice
20/08/2019 17:04
Données d'usage